February 21 2017 Issue

1) Microarray screening of Guillain-Barré syndrome sera for antibodies to glycolipid complexes2) What's Trending: video gaming in children 3) Topic of the Month: Neurology Today® paper on mitochondrial replacementThis podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the February 21, 2017 issue of Neurology. In the first segment, Dr. Ted Burns talks with Dr. Hugh Willison about his Neurology® Neuroimmunology & Neuroinflammation paper on microarray screening of autoantibodies to glycolipid complexes in Guillain-Barre syndrome. Dr. Ted Burns talks with Dr. Gerard Martínez Vilavella about video gaming in children for our "What's Trending" feature of the week. In the next part of the podcast Dr. Ted Burns focuses his interview with Dr. Shoukhrat Mitalipov on mitochondrial replacement for genetic diseases. Disclosures can be found at Neurology.org.DISCLOSURES: Dr. Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc.Dr. Willison serves on the scientific advisory board for Wellcome Trust; serves on editorial boards for Nature Clinical Practice Neurology; Journal of Neuroimmunology, Muscle and Nerve, J Peripheral Nervous System, BMC Neurology (Associate Editor), Clinical and Experimental Neuroimmunology, and Experimental Neurology; holds a patent for combinatorial glycoarray technology; and receives research support from Ipsen, Annexon Biosciences, Alexion Pharmaceuticals, Inc., Medical Research Council, and Wellcome Trust. Dr. Mitalipov holds patents for Primate Totipotent and Pluripotent Stem Cells Produced by Somatic Cell Nuclear Transfer (U.S. patent No. 7,972,849), Human Pluripotent Stem Cells Produced by Somatic Cell Nuclear Transfer (U.S. Patent No. 9,546,383), and Methods for Mitochondrial DNA Replacement in Oocytes (U.S. Patent No. 9434921); has patents pending for Metabolic rescue in pluripotent cells from subjects with mitochondrial DNA disease (Application Number: 62192358), Generation of human oocytes by polar body transfer" (Application 62/419,638), and Mitochondrial Replacement in Human Oocytes Carrying Pathogenic Mitochondrial DNA Mutations (Application 62427546); has consulted for Flagship VentureLabs; and has received research support from NIH/NIA, Burroughs Wellcome Fund, and Foundation Leducq.All other participants report no disclosures.